A direct application is the clinical assessment of lesions suspected of glioma, in particular for the selection of the subsequent clinical steps such as biopsy, resection, or “watch and wait”, but also for risk-stratification in non-contrast-enhancing gliomas (IDH-mut vs. IDH-wt). Here, IDH1 is linked to central nervous system cancer.